Twenty-seven Alzheimer’s drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according analysis presented at the Alzheimer’s Association International Conference (AAIC) by Researchers Against Alzheimer’s (RA2)

these drugs are currently in Phase II and Phase III clinical trials and identifies critical milestones in drug development,

there are also some details on their Mecjanism of action of them there are currently 23 drugs in Phase II and III trials targeting amyloid protein buildup in the brain, while 28 drugs are targeting neurotransmitter activity.